Stock Analysis

RaySearch Laboratories (STO:RAY B) Is Paying Out A Larger Dividend Than Last Year

RaySearch Laboratories AB (publ) (STO:RAY B) will increase its dividend from last year's comparable payment on the 30th of May to SEK3.00. The payment will take the dividend yield to 1.0%, which is in line with the average for the industry.

We've discovered 2 warning signs about RaySearch Laboratories. View them for free.
Advertisement

RaySearch Laboratories' Projected Earnings Seem Likely To Cover Future Distributions

We like to see a healthy dividend yield, but that is only helpful to us if the payment can continue. Prior to this announcement, RaySearch Laboratories' dividend was comfortably covered by both cash flow and earnings. This indicates that quite a large proportion of earnings is being invested back into the business.

Looking forward, earnings per share is forecast to rise by 20.7% over the next year. Assuming the dividend continues along recent trends, we think the payout ratio could be 44% by next year, which is in a pretty sustainable range.

historic-dividend
OM:RAY B Historic Dividend May 23rd 2025

See our latest analysis for RaySearch Laboratories

RaySearch Laboratories' Dividend Has Lacked Consistency

Even in its relatively short history, the company has reduced the dividend at least once. Due to this, we are a little bit cautious about the dividend consistency over a full economic cycle. Since 2016, the annual payment back then was SEK0.25, compared to the most recent full-year payment of SEK3.00. This means that it has been growing its distributions at 32% per annum over that time. Despite the rapid growth in the dividend over the past number of years, we have seen the payments go down the past as well, so that makes us cautious.

The Dividend Looks Likely To Grow

Given that the dividend has been cut in the past, we need to check if earnings are growing and if that might lead to stronger dividends in the future. It's encouraging to see that RaySearch Laboratories has been growing its earnings per share at 25% a year over the past five years. The company's earnings per share has grown rapidly in recent years, and it has a good balance between reinvesting and paying dividends to shareholders, so we think that RaySearch Laboratories could prove to be a strong dividend payer.

RaySearch Laboratories Looks Like A Great Dividend Stock

Overall, a dividend increase is always good, and we think that RaySearch Laboratories is a strong income stock thanks to its track record and growing earnings. Earnings are easily covering distributions, and the company is generating plenty of cash. All in all, this checks a lot of the boxes we look for when choosing an income stock.

It's important to note that companies having a consistent dividend policy will generate greater investor confidence than those having an erratic one. Meanwhile, despite the importance of dividend payments, they are not the only factors our readers should know when assessing a company. For example, we've picked out 2 warning signs for RaySearch Laboratories that investors should know about before committing capital to this stock. If you are a dividend investor, you might also want to look at our curated list of high yield dividend stocks.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About OM:RAY B

RaySearch Laboratories

A medical technology company, provides software solutions for cancer treatment worldwide.

Flawless balance sheet with high growth potential.

Advertisement

Updated Narratives

CE
CEG logo
cementafriend on Constellation Energy ·

Constellation Energy Dividends and Growth

Fair Value:US$348.054.7% overvalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
KH
CRWV logo
Khagani on CoreWeave ·

CoreWeave's Revenue Expected to Rocket 77.88% in 5-Year Forecast

Fair Value:US$11033.5% undervalued
4 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
PO
BIS logo
PortfolioPlus on Bisalloy Steel Group ·

Bisalloy Steel Group will shine with a projected profit margin increase of 12.8%

Fair Value:AU$6.7118.0% undervalued
3 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

TH
TheWallstreetKing
MVIS logo
TheWallstreetKing on MicroVision ·

MicroVision will explode future revenue by 380.37% with a vision towards success

Fair Value:US$6098.4% undervalued
108 users have followed this narrative
10 users have commented on this narrative
21 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$250.3929.3% undervalued
936 users have followed this narrative
6 users have commented on this narrative
24 users have liked this narrative
OS
oscargarcia
GOOGL logo
oscargarcia on Alphabet ·

The company that turned a verb into a global necessity and basically runs the modern internet, digital ads, smartphones, maps, and AI.

Fair Value:US$3405.8% undervalued
144 users have followed this narrative
6 users have commented on this narrative
18 users have liked this narrative